Department of Sports Medicine, Peking University Third Hospital, Institute of Sports Medicine of Peking University, Beijing, 100191, People's Republic of China.
Department of Laboratory Animal Science, Peking University Health Science Center, Beijing, 100191, People's Republic of China.
Int J Nanomedicine. 2024 Nov 13;19:11701-11718. doi: 10.2147/IJN.S466363. eCollection 2024.
Tendon injuries present a significant challenge for independent repair, and can progress into tendinopathy over time, highlighting the importance of early intervention. Dendritic cell-derived exosomes (DEXs) has been shown to shift the polarization of M1 macrophages, the predominant inflammatory cells in the early stages of tendon injury. This study introduces a therapeutic approach that effectively manages inflammation while promoting regeneration in the treatment of tendinopathy.
The purification and characterization of DEXs were meticulously conducted. Experiments were carried out using an Achilles tendon rupture mouse model, with weekly DEXs treatment starting on postoperative day (POD) 4. In vitro, the function of DEXs was assessed by coculturing them with tendon stem/progenitor cells (TSPCs) in culture medium containing IL-1β. Tendon healing progress was evaluated using Sirius Red staining, Masson's trichrome staining, biomechanical testing, and immunofluorescence microscopy. The inflammatory microenvironment of injured tendons was evaluated using the Luminex procedure and flow cytometry analysis.
DEXs treatment significantly enhanced tendon cell differentiation, promoted collagen type I synthesis, and inhibited collagen type III synthesis, thereby expediting tendon healing. Furthermore, DEXs treatment improved the inflammatory microenvironment by reducing multiple cytokines (IL-1β, IL-4, IL-6, TNF-α, and IFN-γ) and induced the conversion of M1 macrophages to M2 macrophages by activating the PI3K/AKT pathway.
DEXs demonstrated a potent ability to promote tendon healing while ameliorating the inflammatory microenvironment, suggesting their potential as a therapeutic approach to prevent the development of tendinopathy.
肌腱损伤的独立修复具有很大的挑战性,随着时间的推移,它可能会发展成肌腱病,这凸显了早期干预的重要性。树突状细胞衍生的外泌体(DEXs)已被证明可以改变 M1 巨噬细胞的极化,M1 巨噬细胞是肌腱损伤早期的主要炎症细胞。本研究介绍了一种治疗方法,该方法在有效管理炎症的同时促进肌腱病的再生。
我们仔细地进行了 DEXs 的纯化和表征。我们使用跟腱断裂小鼠模型进行了实验,从术后第 4 天(POD)开始每周进行 DEXs 治疗。在体外,我们通过将 DEXs 与肌腱干细胞/祖细胞(TSPCs)在含有 IL-1β 的培养基中共培养来评估 DEXs 的功能。我们使用天狼星红染色、马松三色染色、生物力学测试和免疫荧光显微镜评估肌腱愈合进展。我们使用 Luminex 程序和流式细胞术分析评估受伤肌腱的炎症微环境。
DEXs 治疗显著增强了肌腱细胞的分化,促进了 I 型胶原的合成,抑制了 III 型胶原的合成,从而加速了肌腱愈合。此外,DEXs 治疗通过减少多种细胞因子(IL-1β、IL-4、IL-6、TNF-α和 IFN-γ)并通过激活 PI3K/AKT 通路诱导 M1 巨噬细胞向 M2 巨噬细胞转化,改善了炎症微环境。
DEXs 具有促进肌腱愈合和改善炎症微环境的强大能力,表明它们有可能成为预防肌腱病发展的治疗方法。